A new multi-pronged antibody design could help immune cells receive stronger activation signals against cancer. Researchers ...
Researchers at the University of Southampton engineered four-pronged antibodies that cluster the CD27 immune receptor, strongly activating cancer-killing T cells.
Inflammation has to fight pathogens fast—but it can't get out of control. Researchers at the German Cancer Research Center ...
The orchestration of T cell activation is central to immune defence and self-tolerance. Recent advances have revealed that T cells integrate signals from their antigen receptors alongside a network of ...
Among modern cancer therapies, immune checkpoint inhibitors (ICI) are among the most successful treatment methods. These ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Durable reprogramming of human T cells may now be possible thanks to a new technique based on the CRISPRoff and CRISPRon methodology. Researchers from the Arc Institute, Gladstone Institutes, and the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results